Assetmark Inc. Buys 9,612 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Assetmark Inc. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.3% in the 4th quarter, Holdings Channel reports. The firm owned 102,771 shares of the biopharmaceutical company’s stock after purchasing an additional 9,612 shares during the quarter. Assetmark Inc.’s holdings in Halozyme Therapeutics were worth $4,913,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Geode Capital Management LLC raised its position in shares of Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after acquiring an additional 30,901 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock worth $85,254,000 after acquiring an additional 9,780 shares in the last quarter. Boston Trust Walden Corp raised its position in shares of Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after acquiring an additional 191,465 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Halozyme Therapeutics by 60.0% in the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock worth $31,112,000 after acquiring an additional 243,940 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Halozyme Therapeutics by 6.2% in the 3rd quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock worth $31,204,000 after acquiring an additional 31,871 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of several research analyst reports. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Benchmark reissued a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday. Finally, Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Price Performance

HALO stock opened at $60.98 on Friday. The company has a market capitalization of $7.51 billion, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The business has a 50-day simple moving average of $55.70 and a two-hundred day simple moving average of $54.77.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.